Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Treasury Shares (2017 - 2025)

Historic Treasury Shares for Vistagen Therapeutics (VTGN) over the last 11 years, with Q4 2025 value amounting to $4.0 million.

  • Vistagen Therapeutics' Treasury Shares changed 0.0% to $4.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.0 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $4.0 million for FY2025, which is 0.0% changed from last year.
  • Per Vistagen Therapeutics' latest filing, its Treasury Shares stood at $4522.0 for Q4 2025, which was down 0.0% from $4522.0 recorded in Q3 2025.
  • In the past 5 years, Vistagen Therapeutics' Treasury Shares registered a high of $135665.0 during Q1 2021, and its lowest value of $4522.0 during Q1 2022.
  • Over the past 5 years, Vistagen Therapeutics' median Treasury Shares value was $4522.0 (recorded in 2022), while the average stood at $52837.8.
  • In the last 5 years, Vistagen Therapeutics' Treasury Shares changed by 0.0% in 2021 and then decreased by 0.25% in 2023.
  • Over the past 5 years, Vistagen Therapeutics' Treasury Shares (Quarter) stood at $4.0 million in 2021, then changed by 0.0% to $4.0 million in 2022, then changed by 0.0% to $4.0 million in 2023, then fell by 0.0% to $4.0 million in 2024, then changed by 0.0% to $4.0 million in 2025.
  • Its Treasury Shares was $4.0 million in Q4 2025, compared to $4.0 million in Q3 2025 and $4.0 million in Q2 2025.